Advertisement

Topics

Ablynx nv Company Profile

11:07 EDT 20th June 2018 | BioPortfolio

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Location

Technologiepark 4
Ghent
Zwijnaarde
9052
Belgium

Contact

Phone: 32 9 261.06.32
Fax: 32 9 261.06.28
Email: info@ablynx.com


News Articles [166 Associated News Articles listed on BioPortfolio]

Ablynx: ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, 17 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 Feb...

Sanofi to acquire Ablynx

Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs...

Sanofi Wins Antitrust Clearances for Ablynx

Sanofi has received all the necessary regulatory approvals for its planned €3.9 billion takeover of Belgian biotech Ablynx. The deal was announced on Jan. 29. The next step is to launch an acquis...

Ablynx Rejects Novo Nordisk’s $3.1 Billion Acquisition Proposal

GHENT, Belgium, 8 January 2018 – Ablynx NV (Euronext Brussels and Nasdaq: ABLX) (“Ablynx” or the “Company”) today confirmed that on December 22, 2017 it received an unsolicited condition...

Ablynx: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS

REGULATED INFORMATION A year of many momentous moments GHENT, Belgium, 22 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced its financial results for the year ended 31st ...

Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights

Novo Nordisk today confirms that it made a proposal on 22 December 2017 to acquire Ablynx for €28.00 per share in cash and one CVR with total potential cash payments over time of up to €2.50 per s...

Novo Nordisk proposes Ablynx takeover for cash bid of €28/share, CVRs; later outbid by Sanofi

Ablynx NV first announced to the public offers made back in December 2017 by fellow antibody developer Novo Nordisk AS, which initially proposed on December 6th to acquire Ablynx for €26.75 ($31.60;...

Ablynx’s Success Story: The Past, Present and Future

Fintan Walton talks to Edwin Moses, CEO of Ablynx, about the success that the company has enjoyed since its inception, and his plans for it going forward. Edwin talks about the importance of location ...

Drugs and Medications [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therap...

More Information about "Ablynx nv" on BioPortfolio

We have published hundreds of Ablynx nv news stories on BioPortfolio along with dozens of Ablynx nv Clinical Trials and PubMed Articles about Ablynx nv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ablynx nv Companies in our database. You can also find out about relevant Ablynx nv Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record